Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients

1 Nov 2001

Abstract excerpt

Proximal spinal muscular atrophy (SMA) is a common motor neuron disorder caused by mutation of the telomeric survival of motor neuron gene SMN1. The centromeric survival of motor neuron SMN2 gene is retained in all SMA patients but does not produce sufficient SMN protein to prevent the development of clinical symptoms. The SMN1 and SMN2 genes differ functionally by a single nucleotide change. This change affects...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Neurogenetic and Muscular Disorders Research
Share to RNA modifications and cancer
Share to RNA Research and Splicing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 11734549
DOI: 10.1093/hmg/10.24.2841

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patientsPMID 11734549Read ↗

Tetracyclines That Promote SMN2 Exon 7 Splicing as Therapeutics for Spinal Muscular AtrophySemantic proximity Read ↗

RNA in spinal muscular atrophy: therapeutic implications of targeting.Semantic proximity Read ↗

Improved Antisense Oligonucleotide Design to Suppress Aberrant SMN2 Gene Transcript Processing: Towards a Treatment for Spinal Muscular AtrophySemantic proximity Read ↗

<i>SMN2</i> splicing modifiers improve motor function and longevity in mice with spinal muscular atrophySemantic proximity Read ↗

Valproic acid increases SMN levels in spinal muscular atrophy patient cellsSemantic proximity Read ↗

High Concentration of an ISS-N1-Targeting Antisense Oligonucleotide Causes Massive Perturbation of the TranscriptomeSemantic proximity Read ↗

A Negatively Acting Bifunctional RNA Increases <i>Survival Motor Neuron</i> Both <i>In Vitro</i> and <i>In Vivo</i>Semantic proximity Read ↗

Mechanistic principles of antisense targets for the treatment of spinal muscular atrophy.Semantic proximity Read ↗

Specific Correction of Alternative Survival Motor Neuron 2 Splicing by Small Molecules: Discovery of a Potential Novel Medicine To Treat Spinal Muscular AtrophySemantic proximity Read ↗

Targeting SR Proteins Improves SMN Expression in Spinal Muscular Atrophy CellsSemantic proximity Read ↗

Patient-specific responses to <i>SMN2</i> splice-modifying treatments in spinal muscular atrophy fibroblastsSemantic proximity Read ↗

Delivery of bifunctional RNAs that target an intronic repressor and increase SMN levels in an animal model of spinal muscular atrophySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.